当前位置: 首页 > 期刊 > 《中国药房》 > 20183
编号:13600848
色瑞替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌的研究概况(5)
http://www.100md.com 2018年2月1日 《中国药房》 20183
     [13] KATAYAMA R,FRIBOULET L,KOIKE S,et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib[J]. Clin Cancer Res,2014,20(22):5686-5696.

    [14] DONG X,FERNANDEZ-SALAS E,LI E,et al. Elucidation of resistance mechanisms to second-generation ALK inhibitors alectinib and ceritinib in non-small-cell lung cancer cells[J]. Neoplasia,2016 ......
上一页1 2 3 4 5

您现在查看是摘要页,全文长 3487 字符